menu
    • menu
    [{"orgOrder":0,"company":"Venus Remedies","sponsor":"AdjuTec Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"APC-148","moa":"||MBL","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Venus Remedies","highestDevelopmentStatusID":"4","companyTruncated":"Venus Remedies \/ Venus Remedies"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Venus Remedies \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Venus Remedies

    Menu

    Venus Remedies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies VRP-034 receives QIDP designation from US FDA

                            Details : VRP-034 (polymyxin B sulfate) is an antibiotic that disrupts the outer cell membrane of Gram negative bacteria, being investigated for bloodstream infections caused by PMB susceptible strains.

                            Product Name : VRP-034

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 17, 2025

                            Lead Product(s) : Polymyxin B Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APC-148,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : AdjuTec Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AdjuTec, Venus Remedies initiate research collaboration to evaluate APC-148 against AMR

                            Details : Venus Remedies will test APC-148, a selective inhibitor targeting bacterial MBL enzymes, in combination with various antibiotics against multidrug-resistant bacterial strains.

                            Product Name : APC-148

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 26, 2025

                            Lead Product(s) : APC-148,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : AdjuTec Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Secures Regulatory Approvals for Three Key Oncology Drugs in Ukraine

                            Details : Company received marketing authorisations from Ukraine for its three cancer drugs, including paclitaxel, oxaliplatin and irinotecan in various concentrations.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 20, 2024

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Secures Marketing Approval from Israel, Colombia for Two Oncology Drugs

                            Details : Taxedol (docetaxel) is a USFDA approved Tubulin depolymerization inhibitor. It is now approved in Israel for the treatment of breast, prostate, head, neck and non-small cell lung cancer.

                            Product Name : Docetaxel-Generic

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 30, 2023

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bortezomib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Gets Marketing Approval for Six Chemotherapy Drugs from Philippines

                            Details : Bortezomib intravenous injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and adult patients with mantle cell lymphoma.

                            Product Name : Bortezomib-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 16, 2023

                            Lead Product(s) : Bortezomib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium,Sulbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Expands Reach with the Launch of Elores in Ecuador

                            Details : Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.

                            Product Name : Elores

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 14, 2023

                            Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium,Sulbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Gets Marketing Authorisation from UK for Chemotherapy Drug

                            Details : Cisplatin, recently approved in UK, is a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer, and bladder carcinoma.

                            Product Name : Cisplatin-Generic

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Gets Marketing Authorisation for Generic Cancer Drugs from Uzbekistan, Palestine

                            Details : It has received marketing authorisation for its generic alternative cancer drugs carboplatin from Uzbekistan and docetaxel and irinotecan from Palestine.

                            Product Name : Docetaxel-Generic

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies Gets Marketing Authorization from Saudi Arabia for Chemotherapy Drug Docetaxel

                            Details : Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions, by binding to free tubulin and promotes its assembly into stable microtubules while inhibiting...

                            Product Name : Docetaxel-Generic

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 06, 2023

                            Lead Product(s) : Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed

                            Venus Remedies

                            India arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Venus Remedies wins legal battle against French firm for paracetamol patent

                            Details : Venus Remedies had initiated the legal battle in order to remove any patent hurdle in manufacturing of intravenous paracetamol solution in the country.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 17, 2021

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth